Coronavirus vaccine developer CureVac shares surge in U.S. debut

(Reuters) - Shares of German biotechnology firm CureVac BV nearly tripled in their Nasdaq debut on Friday, marking the first stock market debut of a company developing a potential vaccine to combat the novel coronavirus.

Reuters August 15, 2020 00:07:09 IST
Coronavirus vaccine developer CureVac shares surge in U.S. debut

Coronavirus vaccine developer CureVac shares surge in U.S. debut" src="https://images.firstpost.com/wp-content/themes/firstpost/images/220x220_Watermark.jpg" alt=" Coronavirus vaccine developer CureVac shares surge in US debut" width="300" height="225" />

(Reuters) - Shares of German biotechnology firm CureVac BV nearly tripled in their Nasdaq debut on Friday, marking the first stock market debut of a company developing a potential vaccine to combat the novel coronavirus .

The stock opened at $44 per share, up from the initial public offering (IPO) price of $16 per share.

CureVac, backed by Microsoft Corp founder and billionaire Bill Gates, sold 13.33 million shares at $16 apiece, the top end of its indicated price range of between $14 and $16 per share.

The company, which started an early-stage coronavirus trial in healthy volunteers in June with results expected in the final quarter of 2020, raised $213.3 million in the IPO.

Proceeds from the IPO would be used to fund its COVID-19 vaccine program and manufacturing capabilities, CureVac said in a regulatory filing.

The company is working to expand its capacity with a new manufacturing facility in Germany that will be capable of producing billions of vaccine doses.

CureVac is in talks with large drugmakers about a partnership to help market and distribute its prospective vaccine, its chief executive officer told German newspaper Sueddeutsche Zeitung on Friday.

The company is researching how to use messenger RNA to fight cancer, rabies and other illnesses, including the coronavirus .

In June, the German government took a 23% stake in CureVac for about $343 million. In July, GlaxoSmithKline and the Qatar Investment Authority also bought a stake in the company.

Tuebingen-based CureVac secured a 75-million-euro loan from the European Investment Bank last month.

SAP SE co-founder Dietmar Hopp owns a controlling stake in CureVac and is expected to hold a little less than 50% after the listing, according to a company filing.

Bank of America, Jefferies, and Credit Suisse are lead underwriters for the IPO.

(Reporting by Noor Zainab Hussain and Niket Nishant in Bengaluru; Editing by Shounak Dasgupta)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

Pulitzer Prize-winning photojournalist Danish Siddiqui killed in Afghanistan: Politicans, journalists pay tributes
India

Pulitzer Prize-winning photojournalist Danish Siddiqui killed in Afghanistan: Politicans, journalists pay tributes

The Pulitzer prize winner, who was in Kandahar covering operations against Taliban, was killed when he was riding along with the Afghan Special Forces

Indian photojournalist Danish Siddiqui killed during assignment in Afghanistan's Kandahar province
India

Indian photojournalist Danish Siddiqui killed during assignment in Afghanistan's Kandahar province

Siddiqui had also covered the 2020 Delhi riots, COVID-19 pandemic, Nepal earthquake in 2015 and the protests in Hong Kong

Danish Siddiqui's passing is a reminder of the high price one pays for showing the truth
India

Danish Siddiqui's passing is a reminder of the high price one pays for showing the truth

Danish's photographs were not just documentation, but the work of someone who went down to eye-level, as they say in photographic parlance.